Similar Stories to Why Sangamo Therapeutics And Bluebird Bio Slipped Lower Today on Bing News

Sangamo Therapeutics (NASDAQ: SGMO) closed down 10.5% while bluebird bio (NASDAQ: BLUE) slipped 4.8% after competitor Global Blood Therapeutics (NASDAQ: GBT) reported positive data for its sickle cell disease drug, voxelotor.In the part A of Global Blood's phase 3 study, 58% of patients taking the higher dose of voxelotor reached the pre-defined goal of a 1 g/dL increase in hemoglobin, while 38% of the patients taking the lower dose reached the goal, compared to just 9% of patients taking placebo.But that's not even the worse news for Sangamo and Bluebird.Continue reading

BING NEWS:
  • Analysts Offer Insights on Healthcare Companies: Cencora (COR) and Bluebird Bio (BLUE)
    Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cencora (COR – Research Report) and Bluebird ...
    01/6/2025 - 9:41 pm | View Link
  • Bluebird Bio’s Strategic Restructuring and Valuation Uplift Justifies Buy Rating
    Barclays analyst Gena Wang maintained a Buy rating on Bluebird Bio (BLUE – Research Report) yesterday and set a price target of $40.00.Don't ...
    12/30/2024 - 12:36 pm | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News